+49.3%
GSK vs UEC
+156.3%
-107.0%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | UEC | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.7% | +3.0% | -5.7% | -2.7% |
| 7D | -4.2% | +2.6% | -6.8% | -4.2% |
| 30D | -7.5% | +5.6% | -13.1% | -7.5% |
| 3M | -3.3% | -5.7% | +2.4% | -3.3% |
| 6M | -9.3% | -8.0% | -1.3% | -9.3% |
| YTD | +1.6% | +1.8% | -0.2% | +1.7% |
| 1Y | +25.5% | +0.6% | +24.9% | +25.7% |
| 3Y | +49.3% | +155.2% | -105.9% | +44.7% |
| All | +49.3% | +156.3% | -107.0% | +44.7% |
Cumulative growth
Daily Returns
Daily percentage return beside UEC.
Daily Out/Under-Performance
Portfolio return minus UEC return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × UEC return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded UEC wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling